SCHEMBL5113461

SCHEMBL5113461

C#Cc1ccsc1-c1nc2cnccn2c1NC(C)(C)C.c1cc2ccc1-2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 5/20 0.50
TAF1 P21675 1/20 0.50
TAF1L Q8IZX4 1/20 0.50
SALL4 Q9UJQ4 1/20 0.46
GAA P10253 6/20 0.41
MAPT P10636 4/20 0.41
TP53 P04637 1/20 0.41
ALDH1A1 P00352 4/20 0.40
GFER P55789 3/20 0.40
IDO1 P14902 2/20 0.40
MEN1 O00255 1/20 0.40
POLB P06746 1/20 0.40
KMT2A Q03164 1/20 0.40
KDM4E B2RXH2 3/20 0.39
LMNA P02545 1/20 0.39
ADRA1B P35368 1/20 0.39
TUBB4A P04350 1/20 0.38
TUBB P07437 1/20 0.38
TUBA3C P0DPH7 1/20 0.38
TUBA1B P68363 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5127816 0.93 BRD4 (0.54) BRD4TAF1TAF1LSALL4GAA
SCHEMBL5120419 0.93 BRD4 (0.46) BRD4TAF1TAF1LSALL4GAA
SCHEMBL5127406 0.92 SALL4 (0.46) BRD4TAF1TAF1LSALL4GAA
Pyridine SCHEMBL5118643 0.92 SALL4 (0.47) BRD4TAF1TAF1LSALL4GAA
SCHEMBL5127780 0.84 GAA (0.50) BRD4TAF1TAF1LSALL4GAA
SCHEMBL5122934 0.83 GAA (0.51) BRD4TAF1TAF1LSALL4GAA
SCHEMBL5125228 0.82 GAA (0.51) BRD4TAF1TAF1LSALL4GAA
SCHEMBL5113401 0.82 BRD4 (0.53) BRD4SALL4GAAMAPTTP53
Pyridine SCHEMBL5128233 0.82 GAA (0.48) BRD4TAF1TAF1LSALL4GAA
SCHEMBL5113515 0.82 GAA (0.41) GAAMAPTTP53ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1791840-B1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS GRUENENTHAL GMBH (DE) 2013-11-27 EP claimed
US-7420056-B2 Substituted bicyclic imidazo-3-ylamine compounds GRUENENTHAL GMBH (DE) 2008-09-02 US claimed
US-20070155965-A1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS GRUENENTHAL GMBH. (DE) 2007-07-05 US claimed
US-7420056-B2 Substituted bicyclic imidazo-3-ylamine compounds GRUENENTHAL GMBH (DE) 2008-09-02 US disclosed
US-20070155965-A1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS GRUENENTHAL GMBH. (DE) 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155965-A1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PAICS BRD4 83/4885TAF1 4480/4885TAF1L 4586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.